Zai Lab

Zai Lab EBITDA Margin

The EBITDA Margin of Zai Lab (ZLAB) as of Nov 22, 2026 is -48.59 %. In the previous year, EBITDA Margin was -70.71 % — a change of -31.29% (higher).

EBITDA Margin

-48.59 %

YoY

-31.29%

Last updated:

EBITDA Margin of Zai Lab is 2025 -48.59 % . EBITDA Margin of Zai Lab was 2024 -70.71 % . It decreases by -31.29% higher compared to the previous year.

The Zai Lab EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-109,514.01 USD
Jan 1, 2019
-1,564.88 USD
Jan 1, 2020
-616.45 USD
Jan 1, 2021
-485.10 USD
Jan 1, 2022
-188.04 USD
Jan 1, 2023
-137.44 USD
Jan 1, 2024
-70.71 USD
Jan 1, 2025
-48.59 USD
The Zai Lab EBITDA Margin history
YEAREBITDA MarginYoY
-48.59 %-31.29%
-70.71 %-48.55%
-137.44 %-26.91%
-188.04 %-61.24%
-485.10 %-21.31%
-616.45 %-60.61%
-1,564.88 %-98.57%
-109,514.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

EBITDA Margin of Zai Lab is -48.59 % in 2025.

EBITDA Margin of Zai Lab changed from -70.71 % to -48.59 %, representing a -31.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Zai Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Zai Lab with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Zai Lab

All Key Metrics — Zai Lab